
Imperial Innovations supports NanoBioDesign
Imperial Innovations, the technology commercialisation company of Imperial College London, has completed its first investment in a biotech company since its private placement in April 2005. The company has invested into Imperial spin-out, NanoBioDesign, an organisation developing a range of screening systems to speed up the drug discovery process.
Latest News
NB Renaissance, Chequers to exit Biolchim to trade
US conglomerate J.M. Huber has agreed to buy the Italian specialty fertilizers producer
ArchiMed reaps 4x on Bomi sale to UPS
Deal is first full exit from specialist healthcare investor's maiden mid-market fund
GP Profile: Greenpeak Partners on emerging manager fundraising and specialisation
Buy-and-build specialist looks for portfolio add-ons as it contemplates hitting the road for a new fund in 2023
Summa opens North American office
Three existing partners will lead the California office, which is the GP’s first beyond Europe